Chang David D 4
4 · Allogene Therapeutics, Inc. · Filed Mar 24, 2023
Insider Transaction Report
Form 4
Chang David D
DirectorPresident and CEO
Transactions
- Award
Stock Option (Right to Buy)
2023-03-22+1,492,200→ 1,492,200 totalExercise: $5.04Exp: 2033-03-22→ Common Stock (1,492,200 underlying) - Award
Common Stock
2023-03-22+1,924,464→ 4,193,911 total
Holdings
- 1,201,108(indirect: See footnote)
Common Stock
- 856,044(indirect: See footnote)
Common Stock
- 856,044(indirect: See footnote)
Common Stock
Footnotes (5)
- [F1]Includes 1,480,357 of performance RSUs which shall vest as follows: (1) 50% shall vest if the 30-day weighted average stock price is equal to or greater than $18 and (2) 50% shall vest upon the first regulatory approval of a product candidate. Notwithstanding the foregoing (1) any portion that vests upon the stock price threshold shall no longer vest and be terminated after three years from the grant date if such threshold has not been met in such three-year period, and (2) any portion that vests upon product candidate approval shall no longer vest and be terminated after five years from the grant date if such approval has not occurred in such five-year period.
- [F2]Securities held in the name of the Chang 2006 Family Trust
- [F3]Securities held in the name of the JEC 2019 Trust dated October 1, 2019.
- [F4]Securities held in the name of the RTC 2019 Trust dated October 1, 2019.
- [F5]25% of the shares subject to the stock option shall vest on March 13, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter.